Slide 1: Third Quarter 2021 – Financial Results
THIRD QUARTER 2021 – FINANCIAL RESULTS November 2021 Exhibit 99.2
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical fa
Slide 3: Recent Highlights
RECENT HIGHLIGHTS Submitted validation study data from Preecludia™ rule-out test for preeclampsia for publication in peer-reviewed journal Awarded patent for one of the key assays Engaged advisory firm and launched a managed process to license the test to potential commercial partners PREECLUDIA™ TE
Slide 4: Innovation Pipeline Update
INNOVATION PIPELINE UPDATE
Slide 5: Therapeutics Programs
THERAPEUTICS PROGRAMS For drugs that today must be injected, our ingestible capsule technology could enable needle-free, oral delivery and systemic uptake of large molecules. For people who suffer from gastrointestinal diseases, delivering therapeutics directly to the site of disease could enable sa
Slide 6: Therapeutics Pipeline
THERAPEUTICS PIPELINE discovery PGN-OB2 GLP-1 agonist + OBDS PGN-OB1 Adalimumab variant + OBDS Antisense Therapy + OBDS In partnership with IONIS PHARMACEUTICALS Undisclosed Drug + OBDS PGN-001 Adalimumab variant + DDS PGN-600 Tofacitinib + DDS preclinical early clinical late clinical Undisclosed Dr
Slide 7: Therapeutics Programs – Program updates Q3
THERAPEUTICS PROGRAMS ORAL DELIVERY OF BIOTHERAPEUTICS GI-TARGETED THERAPEUTICS ODBS Oral Biotherapeutics Delivery System DDS Drug Delivery System Program updates – Q3 In animals where significant drug was detected Initiated preclinical studies of PGN-OB1 (variant of adalumimab) and PGN-OB2 (GLP-1 a
Slide 8: Preecludia Test Program updates – Q3
PREECLUDIA™ TEST Program updates – Q3 For patients with symptoms of possible preeclampsia, the Preecludia test is potentially the first blood test designed to assess risk by evaluating multiple pathophysiological pathways. RULE-OUT TEST FOR PREECLAMPSIA Submitted PRO-104 validation study manuscript
Slide 9: Near-Term Potential Catalysts
PREECLUDIA publication & ongoing licensing efforts H2 2022 DIAGNOSTICS ORAL BIOTHERAPEUTICS DDS topline clinical PK/PD for adalimumab in ulcerative colitis NEAR-TERM POTENTIAL CATALYSTS Q4 2021 Q1 2022 Q2 2022 GI-TARGETED THERAPEUTICS OBDS preclinical PK data generation DDS device function study in
Slide 10: Operating Expenses
OPERATING EXPENSES
Slide 11: Opex Reductions
OPEX REDUCTIONS Secured $110 million in OPEX1 annual run rate reductions from Q2 2021 Expecting ~$145 million2 total OPEX annual run rate reduction post company transformation Confirming target range of $5 to $6 million monthly cash burn run-rate post transformation Raised ~$79 million during H2 202
Slide 12: progenity
progenity’